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ABSTRACT
The Hepatic CHEMOSAT Delivery System is an
innovative medical device for the treatment of
patients with unresectable primary liver tumors
or unresectable hepatic metastases from solid
organ malignancies. This system is used to
perform chemosaturation percutaneous
hepatic perfusion (CS-PHP), a procedure in
which a high dose of the chemotherapeutic
agent melphalan is delivered directly to the
liver while limiting systemic exposure. In a
clinical trial program, CS-PHP with melphalan
significantly improved hepatic progression-free
survival in patients with unresectable hepatic
metastases from ocular or cutaneous melanoma.
Clinically meaningful hepatic responses were
also observed in patients with hepatocellular
carcinoma or neuroendocrine tumors.
Furthermore, the results of published studies
and case reports demonstrated that CS-PHP
with melphalan resulted in favorable tumor
response rates in a range of tumor histologies
(ocular or cutaneous melanoma, colorectal
cancer, and hepatobiliary tumors). Analyses of
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the safety profile of CS-PHP revealed that the
most common adverse effects were hematologic
events (thrombocytopenia, anemia, and
neutropenia), which were clinically
manageable. Taken together, these findings
indicate that CS-PHP is a promising
locoregional therapy for patients with primary
and secondary liver tumors and has a
acceptable safety profile.
Funding: Delcath Systems Inc., New York, NY,
USA.
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INTRODUCTION
In an effort to control disease, palliate
symptoms, and extend survival, several types of
treatment approaches have been pursued in
patients with primary liver tumors or hepatic
metastases [1–18]. The Hepatic CHEMOSAT
Delivery System (Delcath Systems Inc., New
York, NY, USA) is an innovative medical device
for the treatment of patients with
unresectable primary liver tumors or
unresectable hepatic metastases from solid
organ malignancies, in which a high dose of
the chemotherapeutic agent melphalan is
delivered directly to the liver while limiting
systemic exposure. The concept of the procedure
was developed several decades ago, but is so far
not established in daily clinical practice [19]. The
Hepatic CHEMOSAT Delivery System received
CE mark approval in the European Union (EU)
on April 13, 2011, and the product was launched
commercially in February 2012.
Promising candidates for local ablative
therapies are either patients with primary liver
cancers, such as hepatocellular carcinoma and
cholangiocellular carcinoma, or patients with
extrahepatic cancers and liver-limited disease.
Hepatocellular carcinoma (HCC) is one of the
most lethal and prevalent cancers worldwide. In
2008, there were 748,300 new cases of HCC and
695,900 deaths registered [20]. HCC is
commonly caused by hepatitis B and C
infections (*75%), chronic exposure to toxins
such as aflatoxin B, non-alcoholic and alcohol
steatohepatitis, or less frequently with
hereditary liver diseases. The prognosis of
patients with HCC is dismal and the mortality
rates are almost the same as the incidence rates.
Potentially curative treatments for patients with
early stage disease are liver transplantation (LT),
resection, and radiofrequency or microwave
ablation (RFA/MWA) [21]. Transarterial
chemoembolization (TACE) is the
recommended treatment for patients with
intermediate stage HCC on the basis of two
prospective trials with highly selected patients
and one systematic review and meta-analysis
[22, 23]. HCC is typically resistant to systemic
chemotherapy and the multi-kinase inhibitor
sorafenib is the only approved agent for patients
with advanced disease.
Intrahepatic cholangiocarcinoma (ICC), the
second most common primary liver tumor,
involves a heterogeneous group of
malignancies affecting the biliary epithelium
[24]. Radical resection is the only curative
treatment option. In cases with a potentially
curative surgery, however, 5-year survival rates
of only 25–30% are reported indicating the
unmet need for multimodal treatment
strategies to improve the cure rate of patients
with cholangiocarcinoma [25]. In metastatic
disease, chemotherapy improves quality of life
and survival, and gemcitabine with cisplatin
represents the standard of care on the basis of
recently published phase II and III clinical trials
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[26]. However, all patients ultimately progress
on this therapy, so clinical trials of new and
better agents and innovative treatment
strategies are essential to expand the existing
treatment options for patients with
cholangiocarcinoma.
Metastases to the liver are more common
than primary liver tumors [27]. The liver is the
dominant site of metastatic disease for patients
with a wide variety of primary tumor types,
including ocular melanoma, colorectal
carcinoma (CRC), and neuroendocrine tumors
(NETs) [28–31]. More rarely, hepatic metastases
also arise as the sole site of metastasis in a
subgroup of patients with soft tissue sarcomas,
cutaneous melanoma, breast cancer, ovarian
cancer, thyroid cancer, non-small cell lung
cancer, or renal cell cancer. Local and
locoregional therapies have been shown to be
well tolerated and can contribute to tumor
control in the context of comprehensive
oncologic treatment strategies, and may
prolong survival of patients with liver limited
metastasis. Unfortunately, however, only a few
high-quality clinical trials are available and
randomized prospective clinical trials enrolling
larger numbers of patients need to be carried
out to elucidate the precise value of these
treatments in combination with systemic
chemotherapy.
The objective of this review is to provide a
comprehensive framework to guide clinical
practice in the use of this procedure and the
sharing of clinical experience across multiple
disciplines, including interventional radiology,
anesthesiology, and medical and surgical
oncology. The results of clinical trials of
CS-PHP, as well as retrospective studies and
case reports, are also described. Multiple
discussions, including an investigator meeting
in Paris, among European experts in the field of
CS-PHP formed the basis of this review.
Compliance with Ethics Guidelines
This article does not contain any new studies
with human or animal subjects performed by
any of the authors.
CS-PHP PROCEDURE
Rationale
Delcath Systems has developed a drug/device
combination product as a minimally invasive
alternative to open-surgical isolated hepatic
perfusion (IHP). The product is composed of the
chemotherapeutic agent melphalan
hydrochloride and a number of sterile,
single-use components, including catheters and
an extracorporeal circuit with hemofiltration
cartridges. The Delcath device is used in a
procedure known as CS-PHP to percutaneously
deliver a high dose of melphalan to the liver via
the hepatic artery, while minimizing systemic
exposure to the drug by filtering blood before it is
returned to the systemic circulation.
Chemotherapeutic Agent
Melphalan was selected as the chemotherapeutic
agent for use with CS-PHP because it showed both
efficacy and reversible hepatic toxicity in the
treatment of hepatic metastases from a variety of
tumors, including melanoma, CRC, HCC, and
NETs in the analogous regional procedure of IHP
[32–36]. The principal toxicity of melphalan is
bone marrow suppression, including
thrombocytopenia, anemia, and neutropenia.
Technique
The Hepatic CHEMOSAT Delivery System is
used to conduct CS-PHP. A schematic overview
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of how the components of the CHEMOSAT
Delivery System work together is provided in
Fig. 1.
The CS-PHP procedure is conducted in an
interventional radiology suite with the patient
under general anesthesia. Induction of
anesthesia, intubation, and choice of
anesthetic and muscle relaxant are left to the
discretion of the anesthesiologist. Both central
venous and invasive lines are required, and
arterial pressure must be continuously
monitored. Heart rate, temperature, and
acid–base profile are also measured throughout
the procedure, which takes approximately 3–4 h
to complete.
In CS-PHP, melphalan is delivered directly
into the hepatic artery via a catheter in the
proper hepatic artery. Prior to placement of the
catheter an angiogram of the celiac trunk and
the superior mesenteric artery is performed, the
latter with acquisition of a portal venous phase.
A double-balloon catheter, usually advanced
through the right femoral vein, is positioned
in the inferior vena cava (IVC) with the cranial
balloon in the right atrium–IVC junction and
the caudal balloon in the infrahepatic IVC
above the renal veins to isolate and collect
hepatic venous outflow.
An extracorporeal circuit is established in a
stepwise fashion. First, a closed loop between
Fig. 1 Overview of CS-PHP treatment. Reproduced with permission from Delcath
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the double-balloon catheter and jugular sheath
is created with a centrifugal pump to maintain
flow. The cephalad balloon is filled while still in
the atrium with approximately 20 mL saline
and pulled back. Once this balloon is in
position, the lower balloon is inflated.
Contrast injection is used to exclude leakage
and check for retrograde filling of the hepatic
veins. Blood filtration through two activated
carbon filter cartridges arranged in parallel is
started. Once the extracorporeal circuit is
established and the patient and extracorporeal
blood flow are stable, melphalan is
administered (typically as 100-mL aliquots of
diluted melphalan in 500 mL) via the catheter
positioned in the hepatic artery. After each
aliquot, digital scan angiography is performed
to check for patency and anterograde flow. In
cases of vasospasm, intra-arterial injection of
vasodilators is recommended. Hepatic venous
outflow is sent through an extracorporeal
filtration system to lower the concentration of
melphalan in the blood before being returned
to the systemic circulation via an internal
jugular vein sheath. Extracorporeal filtration
continues for an additional 30 min after
termination of the melphalan infusion to filter
any drug released from the liver; filtration
efficiency is 93%.
Procedure Team
The performance of the CS-PHP procedure
requires a multidisciplinary procedural team
with the knowledge and skills required to care
for patients undergoing this procedure. An
interventional radiologist leads the entire team
during the procedure through communication
and coordination. A surgical or medical
oncologist is responsible for the complete
management of the patient from prior to the
procedure through follow-up. An
anesthesiologist is responsible for general
anesthesia, coagulation management, and
postoperative care. A perfusionist establishes,
monitors, and controls the extracorporeal
circuit. A certified healthcare provider for
chemotherapy delivery (not required in all
countries) is responsible for melphalan
administration. The interventional radiology
staff assists in the procedure and imaging. A
pharmacist is responsible for melphalan
preparation.
Patient Selection
Careful selection of appropriate candidates for
CS-PHP is critical for a successful outcome.
Patients must have either surgically
unresectable primary or metastatic cancer of
the liver. Other evidence-based, local-regional
or systemic treatment options need to be
discussed in a multidisciplinary tumorboard.
Magnetic resonance or computed tomography
imaging of the liver must be completed to
document the position of liver metastases and
evaluate adjacent vascular structures and the
degree of vascularity. A full-body computed
tomography scan should be conducted to
determine whether there is extrahepatic
spread. Patients with a tumor burden
exceeding 50–60% should not be treated
outside of clinical trails, because there is
currently not sufficient evidence for the
long-term benefit and the potentially
increased side effect profile. Patients should
not be treated if they have advanced liver
cirrhosis with portal hypertension or
encephalopathy. Patients must have adequate
hepatic function (Child–Pugh A; total bilirubin
\3.0 mg/dL; aspartate aminotransferase and
alanine aminotransferase \5 times the upper
limit of normal; adequate hematologic function
(hemoglobin [9 g/dL; absolute neutrophil
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count[1.3 cells/lL; platelets[80 thousand per
microliter); and adequate renal function (serum
creatinine \1.5 mg/dL, unless measured
creatinine clearance is [60 mL/min/1.73 m2).
Patients must also have an Eastern Cooperative
Oncology Group (ECOG) score of 0 or 1 before
CS-PHP.
CS-PHP should not be performed in patients
with any of the following:
• Childs B or C cirrhosis or evidence of portal
hypertension by endoscopy or radiologic
imaging
• A history of transient ischemic attacks
• Heart failure, with a left ventricular ejection
fraction\50%
• Significant chronic obstructive pulmonary
disorder or other chronic pulmonary
restrictive disease that would make the
patient ineligible for general anesthesia
• Body weight \35 kg (because of anatomical
and physical limitations with the size of the
double-balloon catheter)
• Severe allergic reactions to iodinated
contrast that cannot be controlled by
antihistamines and steroids
• Prior hypersensitivity reaction to melphalan,
a documented latex allergy, or a history of
hypersensitivity to heparin or presence of
heparin-induced thrombocytopenia
antibodies
• A history of bleeding disorders or evidence of
an intracranial abnormality that puts the
patient at risk for bleeding with
anticoagulation
• A history of gastrinoma
Patient Preparation
Angiographic mapping of the hepatic arterial
circulation with embolization of the
gastroduodenal artery and certain branches
supplying the pancreas, stomach, or duodenum
is recommended to avoid inadvertent reflux of
melphalan into gastrointestinal arterial branches
and gastrointestinal toxicity. Completion is
recommended at least 1 week prior to the
CS-PHP procedure. In patients with a long
proper hepatic artery allowing for secure
positioning of the delivery catheter,
gastroduodenal artery embolization can be
omitted.
Accurate clinical assessment of comorbidities,
particularly exclusion of ischemic heart disease,
is necessary. The patient is admitted to the
hospital the night before for preparation for the
CS-PHP procedure. Intravenous (IV) hydration is
started to ensure an adequate fluid preload before
the procedure; however, this is not consistently
done at all institutions, as some centers believe
that a fluid preload increases the risk of edema,
particularly of the neck, airways, and pulmonary
interstitium. Patients on angiotensin-converting
enzyme inhibitors should discontinue such
medications 2 days before the procedure,
whereas those on other antihypertensive
medications should discontinue these
medications on the day of the procedure. At the
discretion of the procedural team, patients on
beta-blockers may have their dose halved before
the procedure.
Prior to CS-PHP, proton pump inhibitors are
administered to prevent gastritis, which could
occur as a result of regional melphalan
absorption during the procedure. Patients with
a history of hepatobiliary surgery or ablative
procedures are given antibiotics
prophylactically to prevent infections.
Support During and After CS-PHP
Heparin is administered by the anesthesiologist
to maintain activated clotting time at
therapeutic levels. Heparin is administered at
the direction of the interventional radiologist
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before he/she isolates the liver and prior to the
initiation of the extracorporeal circuit by the
perfusionist. Vital signs are monitored
continuously throughout the procedure by the
anesthesiologist.
All patients will experience hypotension at
two points during the procedure: when the
venous balloons are inflated and when the
filters in the bypass circuit are activated [37].
The blood pressure decrease is managed with
prehydration, intraoperative fluid boluses, and
IV vasopressors until blood pressure normalizes.
Vasopressors are administered by the
anesthesiologist to maintain a mean arterial
pressure above 65 mmHg to prevent ischemic
injury to the heart and brain. The mechanism of
hypotension during the filtration phase has not
been clearly elucidated. It was previously
speculated that hypotension was due to
sequestration of catecholamines; however,
some CS-PHP providers believe this is unlikely
since patients always respond with
sympathetic-mediated tachycardia. Other
CS-PHP providers believe hypotension is likely
a systemic inflammatory response with
associated cytokine release or is induced by
nitric oxide. In some institutions, remifentanyl
is not administered for CS-PHP because of its
profound sympathetic suppression, which
makes the hypotensive phase more challenging.
Vasopressor support may be weaned during the
30-min melphalan infusion and is not required
after conclusion of the procedure.
Arterial patency is assessed by the
interventional radiologist several times during
the procedure by injection of contrast media
into the hepatic artery catheter to ensure that
there is no vasospasm of the hepatic artery that
could result in melphalan reflux into proximal
gastrointestinal branches. If hepatic spasm is
seen, nitroglycerin is administered by the
interventional radiologist via intra-arterial
injection. The procedure is terminated by the
interventional radiologist if the spasm does not
resolve with nitroglycerin administration.
After CS-PHP, anticoagulation is reversed
according to the institutional standard of care.
The vascular access sheaths are removed when
coagulation is normal; a vascular occlusion
device might be used to seal the arterial
puncture. Immediately following completion
of the procedure, patients are monitored for
6–16 h at an intermediate care unit or ICU and
then on a general ward for 2–3 days. Early
mobilization and early intestinal motility
(hence oral intake) have been correlated in
some institutions with improved discharge
times to the general ward. Patients must be
periodically monitored for hematologic toxicity
following the procedure for up to 3 weeks and
may require growth factor support or packed




The use of CS-PHP with melphalan was tested in
a formal clinical trial program that included the
following studies:
• Phase 1, single-center [US National Cancer
Institute (NCI)], sequential, dose-escalation
study to determine the maximum tolerated
dose (MTD) of CS-PHP with melphalan in
patients with unresectable hepatic
metastases from cutaneous or ocular
melanoma or other tumor types [38].
• Phase 2, open-label, single-center (NCI),
nonrandomized, uncontrolled study to
examine the efficacy of CS-PHP with
melphalan in patients with
unresectable primary hepatic malignancies
(i.e., HCC or ICC) or unresectable metastatic
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hepatic malignancies from other tumor
types [gastrointestinal adenocarcinoma
(primarily CRC), NET, and cutaneous or
ocular melanoma] [39].
• Phase 3, randomized, controlled,
multicenter study (11 active sites in the
USA) to evaluate the efficacy, safety, and
tolerability of CS-PHP with melphalan
compared with best alternative care (BAC)
in patients with unresectable hepatic
metastases from cutaneous or ocular
melanoma [39]. Patients in the BAC group
were allowed to cross over to CS-PHP at the
time of documented hepatic progression,
provided they continued to meet eligibility
criteria for the study at the time of
crossover. The primary endpoint for this
study was hepatic progression-free survival
(hPFS); secondary endpoints were hepatic
objective response (hOR) and overall
survival (OS).
In the phase 1 study, response was evaluable
in 27 patients (Table 1) [38]. Of 10 patients with
ocular melanoma, 50% had an objective tumor
response and two had a complete response at 10
and 12 months, respectively. Additionally, two
of four patients with hepatic metastases from
NET had ongoing partial responses at 5 and
7 months. Dose-limiting toxicities (DLTs), as
determined by the investigators, are
summarized in Table 2. The MTD of
melphalan delivered by CS-PHP was
determined to be 3.0 mg/kg since only one
patient had a DLT at this dose. All DLTs were
events related to bone marrow suppression,
including neutropenia, febrile neutropenia,
leukopenia, and thrombocytopenia.
In the phase 2 study (Table 3), objective
responses were seen in 75% of ocular
melanoma patients, 12.5% of hepatocellular
carcinoma patients, and 41.7% of NET patients
[39]. In the last of these cohorts, response varied
by type of NET. The hOR rate was 30.8% in
patients with pancreatic NET, 66.7% in those
with carcinoid NET, and 50.0% in those with
other types of NET. All responses were partial
responses. An additional 46.2% of patients
within the pancreatic NET cohort had
stable disease. The most common toxicities
were related to bone marrow suppression, the
known principal toxicity of melphalan,
including thrombocytopenia, anemia, and
neutropenia. Most of these events were not
associated with clinical sequelae.
Table 1 Treatment responses in phase 1 study of CS-PHP [38]
Tumor type Number Partial response Complete response Overall response
n Duration (months) n Duration (months) n %
Ocular melanoma 10 3 7, 9?, 11? 2 10, 12 5 50
Cutaneous melanoma 2 – – – – 0 –
Neuroendocrine 3 2 3?, 7? – – 2 –
Colorectal 1 – – – – 0 –
Adrenal 1 1 10? – – 1 –
Other 7 – – – – 0 –
Total 27* 6 – 2 – 8 29.6
* Of the 27 patients that were assessed for hepatic response only the results of 24 are provided
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In the phase 3 study, 44 patients were
randomized to CS-PHP and 49 to BAC [39].
The majority of patients (81.6%) in the BAC
group received active treatment (most
frequently with temozolamide) whereas 18.4%
of patients received only supportive care. A
clinically meaningful and statistically
significant improvement in hPFS was observed
in the CS-PHP group compared to the BAC
group. Median hPFS was 1.64 months (95% CI
1.48–2.92) in the BAC group compared to
7.03 months (95% CI 5.22–9.66) in the CS-PHP
group (P\0.001). Additionally, there was a
statistically significant (P\0.0001)
improvement in the hOR rate with PHP
(36.4%) compared to BAC (2.0%). Median OS
was similar in the CS-PHP and BAC groups;
however, these results are confounded by the
high number of BAC patients (57.1%) who
crossed over to CS-PHP treatment. Of the 49
patients originally assigned to BAC, 28 had
hepatic disease progression and crossed over to
receive CS-PHP. A post hoc analysis examined
outcomes in these patients compared to those
in the BAC group who had not crossed over to
CS-PHP and those originally assigned to CS-PHP
[40]. The baseline characteristics of the
crossover group were comparable to the
groups who received BAC only and those who
were initially randomized to CS-PHP [39]. The
analysis of outcomes in this post hoc analysis
showed that the efficacy of CS-PHP in the
Table 2 DLTs in phase 1 study [38]
Melphalan dose (mg/kg)
2.0 (n5 14) 2.5 (n5 3) 3.0 (n 5 10) 3.5 (n5 6)
No. of patients with a DLT 0 0 1 2
Decreased neutrophil count 0 0 – 2
Decreased white blood cell count 0 0 1 1
Decrease platelet count 0 0 1 2
Febrile neutropenia 0 0 1 1
DLT dose-limiting toxicity











CR 0 0 0 0
PR 10 1 3 0
SD 6 4 1 4
PD 3 1 0 5
Not available 5 2 0 8
CR complete response, PD progressive disease, PR partial response, SD stable disease
a Excluding three patients enrolled, but not treated
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crossover group was similar to that in the group
initially randomized to this therapy. The
median hPFS was 8.0 in the CS-PHP group and
1.6 in the BAC group that had not crossed over
to CS-PHP (P\0.0001). The crossover group
had an hPFS of 8.8 months, which was
comparable to that in the group initially
treated with CS-PHP. The median OS was
9.8 months in the CS-PHP group as opposed to
4.1 months in the BAC-only group and
15.3 months in the crossover group. As was
seen in the phase 2 study, the toxicity profile in
the phase 3 study was characterized by adverse
events related to bone marrow suppression,
including thrombocytopenia, neutropenia, and
anemia. Most of these events were not
associated with clinical sequelae.
Retrospective Studies
In addition to the results of the clinical trial
program, several retrospective studies reported
outcomes data for CS-PHP with melphalan
(summarized in Table 4). A total of four
noncomparative studies were conducted
[41–44]. One of the noncomparative studies
enrolled 13 patients [44], 10 of whom were also
included in a separate comparative retrospective
analysis [45]. In addition, two case reports were
published [46, 47]. All of the studies reported
hepatic response data; two of the studies also
reported toxicity data [41, 43].
In the noncomparative studies of CS-PHP
with melphalan for the treatment of
unresectable hepatic metastases, patients had a
variety of primary tumor types, including ocular
melanoma, cutaneous melanoma, CRC,
leiomyosarcoma, breast cancer,
cholangiocarcinoma, and gastric cancer
(Table 4) [41–44]. Among the 54 patients in
these four studies, hepatic response rates by
RECIST criteria were 58%, 75%, 70%, and
61.5%, respectively. Hepatic responses were
seen in patients with cholangiocarcinoma,
CRC, ocular melanoma, and cutaneous
melanoma, with complete responses in one
patient with cholangiocarcinoma and two
patients with ocular melanoma. Stable disease
was also observed with CS-PHP in patients with
ocular melanoma, cutaneous melanoma,
melanoma with unknown primary,
leiomyosarcoma, breast cancer, and gastric
cancer.
Toxicity data were reported in the
noncomparative study by Vogl et al. [41].
Toxicities following CS-PHP were consistent
with the toxicity profile seen in the clinical
trials of CS-PHP with melphalan. The most
common adverse effects were hematologic
events (thrombocytopenia, anemia,
neutropenia), which were managed effectively
with supportive measures. Three patients were
initially treated with the first-generation filter,
then switched to the second-generation filter,
providing an opportunity for a comparison of
toxicity profiles with the two systems. Toxicity
was less severe and patients required fewer
supportive measures (i.e., no transfusions,
shorter courses of colony stimulating factors)
with the second-generation filter than the
first-generation filter.
The comparative study was a retrospective
evaluation of outcomes at a single institution in
a small number of patients (N = 30) with
unresectable hepatic metastases from ocular
melanoma, cutaneous melanoma, or an
unknown primary tumor who received a
liver-directed therapy between 2008 and 2014
(Table 4) [37]. Liver-directed therapies included
yttrium, chemoembolization, and CS-PHP. One
patient was treated with yttrium after CS-PHP
and one patient was treated with CS-PHP after
chemoembolization; both of these patients
were excluded from the efficacy analyses.
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Kaplan–Meier survival estimates, log-rank test,
and multivariate Cox regression analyses were
used to relate patient, tumor, and treatment
variables to hPFS and OS.
There were no differences between the
yttrium, chemoembolization, and CS-PHP
groups with regard to age, adjuvant therapy,
prior regional hepatic treatment, or
complications following treatment.
Extrahepatic disease was more prevalent in the
chemoembolization group (P = 0.004)
compared with the yttrium and CS-PHP
groups. The ECOG score trended lower in the
CS-PHP group (P = 0.051) compared with the
yttrium and chemoembolization groups.
Median hPFS was significantly (P = 0.002)
longer with CS-PHP (310 days) than with
yttrium (54 days) and chemoembolization
(80 days) [36]. Median hPFS was also
significantly longer with CS-PHP versus
yttrium (P\0.001) and CS-PHP versus
chemoembolization (P = 0.008), but not
yttrium versus chemoembolization (P = 0.44).
A higher ECOG score (P = 0.01) and a greater
tumor burden (P = 0.03) were correlated with a
shorter duration of hPFS. Median OS was longer
with CS-PHP (736 days) than with yttrium
(285 days) and chemoembolization (265 days);
this difference was significant for CS-PHP versus
yttrium (P = 0.03). Neither ECOG score nor
tumor burden were significant predictors of OS.
Case Reports
Two case reports for CS-PHP with melphalan
have been published (Table 4) [46, 47]. Hofman
et al. reported the case of a 40-year-old woman
with unresectable hepatic metastases from a
solid pseudopapillary neoplasm of the pancreas
who had progressive liver disease after 3 months
of systemic chemotherapy (gemcitabine and
cisplatin) [47]. CS-PHP was performed twice
within 8 weeks and a partial response was
observed. The patient recovered rapidly after
each CS-PHP procedure. Grade 3 leukopenia was
seen after the second procedure and was
effectively managed with granulocyte colony
stimulating factor. No other toxicities were
evident.
Deneve et al. described the case of a
66-year-old woman with isolated bilobar
unresectable hepatic metastases from
leiomyosarcoma [46]. Four target hepatic
lesions were identified and monitored to assess
treatment response. The patient underwent four
CS-PHP procedures with melphalan. A 25%
reduction in the size of the largest target
lesion was observed, and the hPFS was
16 months. With the first CS-PHP procedure,
the patient had mild bone marrow suppression,
including thrombocytopenia and neutropenia,
which were managed with filgrastim and
platelet transfusion, respectively. Minimal
toxicity and a more rapid recovery were seen
with the second CS-PHP procedure.
Post-approval Experience with CS-PHP
in Europe
As of July 31, 2016, 186 patients in the EU had
received a total of 321 CS-PHP treatments
(Table 5). Most procedures were performed for
patients with liver metastases from ocular
melanoma. The majority of procedures were
performed in Germany (75 procedures total in
11 hospitals), the UK (49 procedures total in
four hospitals), and the Netherlands (33
procedures total in two hospitals). CS-PHP was
also performed in Italy (12 procedures total in
two hospitals), France (nine procedures total in
two hospitals), Spain (six procedures total in
two hospitals), Ireland (one procedure total in
one hospital), and Turkey (one procedure in one
hospital).
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An EU registry has been initiated to collect
safety, efficacy, and resource utilization data for
patients who have received CS-PHP for
treatment of an unresectable hepatic
malignancy. Delcath is contacting its list of
authorized customer hospitals that have been
supplied the Hepatic CHEMOSAT Delivery
System to request that they identify patients
who have received or who will be receiving
CS-PHP treatment for inclusion in this registry.
Efficacy data that will be collected include
hepatic response to treatment; time to partial
response or complete response; time to liver
metastasis progression; time to extrahepatic
disease progression, and overall survival. Safety
data that will be collected include laboratory
test results; length of postoperative stay; blood
product use; hospital admission and reason for
admission within 30 days following CS-PHP;
disease- and treatment-related adverse events;
supportive care (i.e., growth factors and
antibiotics); performance status; tumor-related
symptoms; and quality of life. The registry will
end when data for 200 patients have been
accrued.
Ongoing Clinical Studies
A number of clinical studies with CS-PHP are
either ongoing or planned. A summary of these
studies is provided in Table 6.
CONCLUSIONS
CS-PHP with melphalan is an effective regional
treatment option for patients with
unresectable primary or hepatic metastases.
The toxicities associated with CS-PHP are in
most cases transient and manageable. In the
clinical trial program (specifically, the
randomized, controlled phase 3 study),
CS-PHP with melphalan resulted in a clinically
meaningful and statistically significant
improvement in hPFS in patients with
unresectable hepatic metastases from ocular or
cutaneous melanoma. Clinically meaningful
hepatic responses in patients with
hepatocellular carcinoma or NET were also
observed in the clinical trial program. The
safety profile of CS-PHP with melphalan is well
characterized, consisting primarily of bone
marrow suppression (i.e., neutropenia, anemia,
and thrombocytopenia). These toxicities can be
addressed by a combination of patient selection
criteria, patient monitoring, and appropriate
intervention.
In addition, results from a number of
published studies and case reports indicate
that CS-PHP with melphalan may also be a
Table 5 Number of CS-PHP treatments in Europe by
tumour type















CRC colorectal cancer, CS-PHP chemosaturation
percutaneous hepatic perfusion, HCC hepatocellular
carcinoma, NET neuroendocrine tumor
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therapeutic option for other primary and
secondary liver tumors providing the rationale
for ongoing and planned clinical trials across a
spectrum of tumor histologies including ocular
or cutaneous melanoma, CRC, and
cholangiocarcinoma.
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